PM360

SEPTEMBER 15, 2022

In many of the states where abortion is banned, strictly regulated, or soon to be restricted, the procedure is legal only in instances of a life-threatening situation, but no regulations define what such a situation may be, leaving 70% of physicians unclear about when to intervene for maternal safety. FDA Update. Drug Approvals.

Healthcare 52

Healthcare Healthcare Doctors Physicians 52

Pharmaceutical Technology

APRIL 18, 2023

Members of the FDA’s Antimicrobial Drugs AdCom voted 12-0 for the drug’s potential approval based on a positive benefit-risk assessment. The agency accepted the drug’s new drug application (NDA) for priority review in November 2022. The application’s PDUFA date was set to 29 May 2023. Entasis is a subsidiary of Innoviva.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Food 52

Legacy MEDSearch

SEPTEMBER 26, 2023

Food and Drug Administration (FDA) has approved MRI conditional labeling for the Evoke ® System, the first and only precision, dose-control spinal cord stimulation (SCS) therapy powered by SmartLoop technology. Specific scan conditions and safety information are provided in the Evoke ® SCS System MRI Guidelines manual. Are you hiring?

Medical 52

Medical FDA Food and Drug Administration Safety 52

pharmaphorum

SEPTEMBER 30, 2022

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. — The ALS Association (@alsassociation) September 29, 2022.

FDA 87

FDA Doctors Patients Prescription 87

Legacy MEDSearch

AUGUST 15, 2022

“The current version will enable reproducible analysis of patient data which will provide immediate value for our current and future biologics and drug delivery partners as they study volumetric infusion characteristics and longitudinal patient comparisons as part of their safety and pivotal trials. About ClearPoint Neuro. Are you hiring?

FDA 98

FDA Recruitment Safety Patients 98

Pharmaceutical Technology

APRIL 26, 2023

The US Food and Drug Administration (FDA) has granted orphan drug designation to IN8bio’s INB-400 and INB-410 to treat a range of malignant gliomas, including newly diagnosed glioblastoma multiforme (GBM). This marks the first-ever designation for genetically modified gamma-delta T cell therapies.

Food and Drug Administration 52

Food and Drug Administration FDA Engineering Food 52

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Read on to for insights from our analysts on: Global highlights from ESMO 2022. Key ESMO 2022 highlights from Mainland China. Seven global highlights from ESMO 2022.

Marketing 52

Marketing Safety Patients Competition 52

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. This “skinny” bill passed just in time to continue funding the FDA, with few of the planned amendments. billion in funding, a $226 million increase on the previous year.

FDA 52

FDA Prescription Medicine Biopharma 52

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 The emergency use approval from the FDA of lipid nanoparticle- (LNP-) based mRNA vaccines during the COVID-19 pandemic attested the significance of LNPs.

Food and Drug Administration 86

Food and Drug Administration Transportation FDA Medical 86

PM360

AUGUST 9, 2022

The industry has been limited in its ability to implement creative solutions to engage and motivate patients because the FDA has strict guidelines for what pharma companies can communicate with patients. Measuring and monitoring adherence in clinical trials would add valuable information about the effectiveness and safety of drugs.

Medical 105

Medical Electronics Patients Healthcare 105

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Consequently, the US Food and Drug Administration (FDA) and other agencies are keen to see “accelerated development” programmes in areas where there is a significant unmet clinical need. He is currently a CMC consultant with an interest in impurities and safety‑based limits. FDA; 2018 [cited 2023Jan]. Internet] 2022.

Food and Drug Administration 74

Food and Drug Administration FDA Safety Food 74

Impetus Digital

JUNE 8, 2022

It used to take years for a drug to progress from laboratory research to FDA approval. The FDA’s recently-launched Real-Time Oncology Review program is a good example of this modernization. The post The Latest Biotech Trends of 2022 appeared first on Impetus Digital. Faster Pharmaceutical Testing and Approvals.

Medicine 52

Medicine FDA Leads Distribution 52

European Pharmaceutical Review

DECEMBER 13, 2022

The following year, the US Congress passed the 1938 Federal Food, Drug and Cosmetic (FD&C) Act, which mandated safety assessments prior to the release of any new drug. There is now global awareness of this issue and FDA issued a guidance note on the problem in 2007. 05 October 2022. 400(10361); 2022; 1395. References.

Food and Drug Administration 90

Food and Drug Administration Manufacturing Safety Food 90

European Pharmaceutical Review

DECEMBER 21, 2022

But in early 2022, the country’s health minister announced his approval of research into psychedelic therapies and increased funding for mental health research. 3 This notice came on the heels of a January 2022 notice that clarified Health Canada’s desired approach to psilocybin research. Breakthrough therapy designation.

Food and Drug Administration 105

Food and Drug Administration Medicine Food Government 105

pharmaphorum

SEPTEMBER 29, 2022

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin disease following a priority review. Kim (@itchdoctor) September 29, 2022. The suffering he notes from the #itch is 100… [link]. — Brian S.

FDA 67

FDA Patients Leads Safety 67

European Pharmaceutical Review

NOVEMBER 29, 2023

Following the US Food and Drug Administration (FDA)’s approval of Ferring Pharmaceuticals’ gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg) in December 2022, new long-term follow up data has been revealed. The KM-estimated median duration of HG recurrence-free survival was six months, with a 30.1

Food and Drug Administration 90

Food and Drug Administration FDA Pharmaceutical Food 90

European Pharmaceutical Review

JANUARY 29, 2024

4 The use of CPCA assessments allows for the assignment of scientifically justifiable higher acceptable intakes (AIs), without impacting patient safety. During August 2023 the FDA also updated its guidance for NDSRIs 7 and it was closely aligned (but not identical) to EMA’s evolving guidance. ng/day, compared to EMA which is 18 ng/day.

Pharmaceutical 94

Pharmaceutical Food and Drug Administration Medicine FDA 94

European Pharmaceutical Review

JANUARY 26, 2024

The US Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) as a treatment for children patients aged one to 11 years, weighing at least 15kg with eosinophilic esophagitis (EoE). This new authorisation by the FDA’s expands its initial approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40kg.

Medicine 79

Medicine Food and Drug Administration FDA Food 79

Legacy MEDSearch

JULY 27, 2022

Rapid Medical , a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER 13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto. TIGERTRIEVER 17 and 21, COMANECI , and COLUMBUS /DRIVEWIRE are CE marked and FDA cleared.

Medical 52

Medical FDA Recruitment Physicians 52

Legacy MEDSearch

AUGUST 25, 2022

Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) technology. said Olivier Delporte, CEO. About Miracor Medical. Press Release by: Miracor Medical.

Medical 52

Medical FDA Recruitment Pharmacology 52

Pharmaceutical Technology

APRIL 5, 2023

Shionogi has obtained fast track designation from the US Food and Drug Administration (FDA) for its ensitrelvir fumaric acid, an investigational oral antiviral drug for the treatment of Covid-19. Shionogi is currently investigating the safety and efficacy of ensitrelvir across Covid-19 patient groups in a number of Phase lll trials.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

PM360

OCTOBER 27, 2022

Krystal’s Phase 3 randomized, double-blind, intra-patient placebo-controlled study evaluated the efficacy and safety of B-VEC as a redosable gene therapy in DEB patients aged 6 months and older. Subjects returned to the clinical site 30 days following the last dosing visit for safety evaluation by the trial investigator.

Safety 104

Safety Patients FDA Medical 104

European Pharmaceutical Review

DECEMBER 5, 2022

MOMENTUM was a randomised, double-blind Phase III clinical trial of momelotinib versus danazol in symptomatic and anaemic myelofibrosis patients treated with a US Food and Drug Administration (FDA)-approved JAK inhibitor.

Food and Drug Administration 73

Food and Drug Administration Marketing Food Medicine 73

Pharmaceutical Technology

MAY 9, 2023

The US Food and Drug Administration (FDA) has granted Vedanta Biosciences’ oral microbiome treatment VE303 a fast track designation for the treatment of recurrent Clostridioides difficile (C.diff) infection, as the company plans to start a Phase III trial later this year, based on a May 8 announcement. diff infections every year in the US.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

European Pharmaceutical Review

NOVEMBER 7, 2022

has announced its B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb) elranatamab for relapsed or refractory multiple myeloma (RRMM) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA). The investigation noted elranatamab delivered a manageable safety profile. Pfizer Inc.

Food and Drug Administration 92

Food and Drug Administration Medicine Safety FDA 92

Nixon Gwilt Law

APRIL 22, 2024

The rule aims to regulate and enhance the transparency, effectiveness, and safety of predictive DSIs used in healthcare settings, ensuring that these technologies are developed and managed responsibly. FDA’s guidance on SaMD, CDSS, and other mobile applications does not contemplate the advent of generative AI technologies.

Healthcare 52

Healthcare Healthcare Training Food and Drug Administration 52

European Pharmaceutical Review

JANUARY 26, 2023

These concentration measurements are used as part of regulatory decisions regarding the safety and efficacy of medicinal products. The US Food and Drug Administration (FDA) implementation date was 7 November 2022. The draft ICH M10 guideline was published for comments in 2019.

Food and Drug Administration 85

Food and Drug Administration Medicine Pharmaceutical products Pharmaceutical 85

Pharmaceutical Technology

DECEMBER 11, 2022

Due to the rarity of the disease, no FDA-approved therapy exists specifically for RT, and these patients are treated using regimens derived from the DLBCL treatment paradigm and other small-scale clinical trials. of patients discontinued treatment due to adverse events.

FDA 59

FDA Patients Safety Pharmaceutical 59

European Pharmaceutical Review

MAY 4, 2023

Data announced at the European Lung Cancer Congress (ELCC) earlier this month revealed the long-term efficacy and safety of RYBREVANT ® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). 2022; 10(1). 2022; 24(2): 89 – 97. References 1. Garrido P et al.

Food and Drug Administration 89

Food and Drug Administration Safety Medicine Patients 89

pharmaphorum

DECEMBER 5, 2022

No unexpected safety findings were observed in the PSMAfore trial and data was consistent with Pluvicto’s already established safety profile. The findings will be presented at an upcoming medical meeting and submitted to the FDA for regulatory approval in 2023.

Medicine 57

Medicine Safety FDA Healthcare 57

Pharmaceutical Technology

MAY 10, 2023

In July 2022, Alvotech commenced a trial to compare AVT06 and Eylea for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD). The trial has been designed to assess the efficacy, safety and immunogenicity of the therapy combination in the targeted patients. “We

Food and Drug Administration 52

Food and Drug Administration Food Safety Marketing 52

European Pharmaceutical Review

OCTOBER 6, 2022

The US Food and Drug Administration (FDA) has approved Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) test), which identifies low HER2 expression in metastatic breast cancer. Enhertu’s safety profile was consistent with earlier clinical trials, demonstrating no new safety concerns.

Food and Drug Administration 74

Food and Drug Administration Patients Safety Food 74

Pharmaceutical Technology

APRIL 28, 2023

The US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to Editas Medicine’s gene therapy EDIT-301 in sickle cell disease, based on an April 27 announcement. The US agency previously granted the Orphan Drug Designation to EDIT-301 for its study in beta thalassemia, in May 2022. g/dL and 45.4%

Food and Drug Administration 105

Food and Drug Administration Engineering Patients Food 105

European Pharmaceutical Review

DECEMBER 6, 2023

The US Food and Drug Administration (FDA) has approved the first oral monotherapy treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH). Over one-third of those patients require blood transfusions at least once per year, according to research published in a 2017 paper in Blood and a 2022 paper in Annals of Hematology.

Food and Drug Administration 82

Food and Drug Administration Patients Physicians Food 82

Pharmaceutical Technology

MAY 12, 2023

Editas Medicine will release new efficacy and safety results of its gene therapy EDIT-301 in severe sickle disease as part of an oral presentation at the European Hematology Association’s (EHA) Hybrid Congress. Last month, the US Food and Drug Administration (FDA) granted the treatment an orphan drug designation for sickle cell disease.

Food and Drug Administration 98

Food and Drug Administration Food Safety Patients 98

European Pharmaceutical Review

AUGUST 31, 2023

Overcoming challenges in patient safety, manufacturing and supply of radiopharmaceuticals As clinical trials progress and the first results are published, companies’ best candidates will emerge in the next five years. Hospital staff must also be protected from radiation while handling the agent.

Food and Drug Administration 75

Food and Drug Administration Manufacturing Safety Transportation 75

Pharmaceutical Technology

MAY 22, 2023

Intercept Pharmaceuticals faced a setback after a US Food and Drug Administration’s (FDA) Advisory Committee (AdCom) meeting on the prospective use of its drug Ocaliva in pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH) did not go in its favour. Ocaliva is a farnesoid X receptor agonist.

Medicine 59

Medicine FDA Prospecting Food 59